Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Padeliporfin · WST-11

Small molecule · developed by Impact Biotech

Phase 3 Most advanced trial
1 Registered trials

What is Padeliporfin?

Padeliporfin is a water-soluble, palladium-substituted bacteriochlorophyll photosensitizer. It is activated locally by low-power laser light in the tumor bed, forming reactive oxygen species that cause vascular-targeted necrosis of tumor tissue. It is studied in transitional cell cancer of the renal pelvis and ureter.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
WST-11
Drug type
Small molecule
Pathways
vascular-targeted photodynamic therapy, reactive oxygen species formation
Therapy area
Oncology
Developer
Impact Biotech Ltd
In trials of
ICLR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
EEO29FZT86

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04620239 Phase 3 Transitional Cell Cancer of Renal Pelvis and Ureter Active not recruiting ICLR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Transitional Cell Cancer of Renal Pelvis and Ureter

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.